Regorafenib to be fast-tracked by US authorities

The assessment of Bayer HealthCare’s investigational drug regorafenib for the treatment of stomach tumoursis to be fast-tracked by US authorities for the treatment of stomach tumours Click here to read the report.

Posted in GIST News.